Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...
October 07, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq ... the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and ...
In the latest market close, Gilead Sciences (GILD) reached $85.21 ... Heading into today, shares of the HIV and hepatitis C drugmaker had gained 6.64% over the past month, outpacing the Medical ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...